Form 10-K for the Fiscal Year Ended December 31, 2024
We reference your response to prior comment 1. It appears that the non-GAAP adjustment for the purchase of royalty interest is related to a normal recurring operating expense for which a non-GAAP adjustment would be inconsistent with Question 100.01 of the Compliance & Disclosure Interpretations (C&DI) for Non- GAAP Financial Measures.Rest of the question
In that regard, we note that the underlying intellectual property developed in connection with the related agreements continues to be incorporated into the company's products. Therefore, it appears that those costs relate to the generation of revenue and would be considered normal operating expenses. Please revise your presentation to remove the adjustment for purchase of royalty interest from your Adjusted EBITDA measures in future filings as well as the presentation of Adjusted Net Income included in the press release on Form 8- K. Alternatively, tell us why you continue to believe that the adjustment is consistent with the C&DI.
No numbered answer found in the reply. Read the reply ↗
First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.
Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.
Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.
Net loss and Net loss from continuing operations increased $15.6 million during 2023 2025 in comparison to 2022, 2024, primarily due to one-time income items the increase in Goodwill impairment charges of $404.8 million, a $45.8 million increase in charges for the prior year period, including the Unrealized gain on investment Purchase of royalty interest and an $8.1 million increase in ESAB Corporation, Gain on cost basis investment, Insurance settlement gain, amortization of acquired intangibles, partially offset by the reduction of debt extinguishment charges and the aforementioned net impact of the Gross profit and Selling, general, and administrative increases as well as the increase in gross profit, a $48.0 million decrease in Interest restructuring and strategic transactions costs from Lima and other integration activities, and a $22.3 million decrease in interest expense, net and the impact of unfavorable discrete tax items in 2022. net. Adjusted EBITDA increased due to organic growth. Adjusted the growth in Recon and improved operating leverage.
Net sales increased in Recon by $379.3 million, or 60%, of which $338.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a $4.3 million decrease from the discontinuance of certain non-core product lines. Comparable Sales Growth for Recon was driven by approximately 8.2% increase in volume and market share gains and favorable currency translation of 0.3%. Gross profit increased $179.1 million in the year ended December 31, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, and improved operating leverage, offset by an increase of $51.6 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by $207.6 $8.3 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased an increase in commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, sales and increases in existing business investments to support growth. growth, nearly entirely offset by a decrease in Lima Acquisition integration costs. Research and development expense increased compared to the prior year period due to the Lima Acquisition an increase in new product development projects and increased activities and spending within other our recently acquired businesses in our Recon segment, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due Purchase of royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a Goodwill impairment fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and recognized a $45.8 million charge of $330.0 million, a $48.9 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization net present value of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage. purchases.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
Reference the non-GAAP adjustment related to Inventory step-up. Please tell us why you believe an adjustment for inventory step-up charges in connection with acquired businesses does not change the recognition and measurement principles required to be applied in accordance with GAAP. Refer to Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures.Rest of the question
Alternatively, please revise your presentation to remove this non-GAAP adjustment to Adjusted net income and Adjusted EBITDA measures in future filings, including the presentation in the press release on Form 8-K.
No numbered answer found in the reply. Read the reply ↗
First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.
Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.
Net sales increased in Recon by $379.3 million, or 60%, of which $338.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a $4.3 million decrease from the discontinuance of certain non-core product lines. Comparable Sales Growth for Recon was driven by approximately 8.2% increase in volume and market share gains and favorable currency translation of 0.3%. Gross profit increased $179.1 million in the year ended December 31, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, and improved operating leverage, offset by an increase of $51.6 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by $207.6 $8.3 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased an increase in commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, sales and increases in existing business investments to support growth. growth, nearly entirely offset by a decrease in Lima Acquisition integration costs. Research and development expense increased compared to the prior year period due to the Lima Acquisition an increase in new product development projects and increased activities and spending within other our recently acquired businesses in our Recon segment, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due Purchase of royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a Goodwill impairment fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and recognized a $45.8 million charge of $330.0 million, a $48.9 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization net present value of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage. purchases.
Net sales increased for Recon in the year ended December 31, 2023 compared with the prior year, by $94.9 million, or 17.7%, primarily due to higher sales volumes driven by broad market strength and market outperformance. Gross profit increased in the year ended December 31, 2023 compared to the prior year, by $82.1 million, primarily due to increased sales in our existing businesses, improved operating cost leverage, and the benefit of a decrease of $12.7 million in inventory fair value step-up amortization charges, which also led to an increase in Gross profit margin. Selling, general and administrative expense increased $53.6 million, including an increase of $43.1 million, or 15%, due to the growth in Recon from increased commissions driven by higher sales, investments to support growth, spending on MDR, and cost inflation, as well as a net increase in Strategic transactions costs of $3.9 million from an increase in deal and integration costs for the Lima and Novastep acquisitions offset by a decrease of Separation costs. Research and development expense increased compared to the prior year period, primarily due to increased spend within recently acquired businesses which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss decreased primarily due to the aforementioned factors driving organic growth, offset by an insurance settlement gain recorded in the second quarter of 2022 and an increase of $6.2 million in amortization of acquired intangibles. Adjusted EBITDA increased primarily due to growth in existing businesses and operating leverage, partially offset by inflation of supply chain, logistics, and other costs. Without the impact of recent acquisitions, Adjusted EBITDA increased 150 basis points compared to prior year. The recent acquisitions of Novastep and 360 Med Care were dilutive to the margin by approximately 70 basis points but are expected to be accretive to margins in future years.
Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
We note that you continue to include material non-GAAP adjustments for strategic transaction costs. Please tell us why you continue to adjust your non-GAAP measures for these costs and explain why they are not normal, recurring cash operating costs. With your response, please include information abut the expenses/(benefits) incurred through September 30, 2025.Rest of the question
In addition, describe in more detail the nature of the payroll costs and retention expenses for which non-GAAP adjustments were made in 2024 and 2025. Please reference Question 100.01 of the C&DI for Non-GAAP Financial Measures.
No numbered answer found in the reply. Read the reply ↗
First report after the company's reply of Jan 30, 2026: 10-K filed Feb 26, 2026 ↗, against the 10-K filed Feb 26, 2025 ↗.
Non-GAAP Measures: 76 paragraphs changed; the 3 closest in words to the question are below.
Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other income, income (expense), net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; strategic purchase of economic interest on future royalty payments; goodwill impairment charges; and fair value charges on acquired inventory. inventory step-up. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.
(5) Strategic transaction costs includes: (i) $39.4 million for the year ended December 31, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $19.5 million for the year ended December 31, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $1.5 million for the year ended December 31, 2025 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
(5) Strategic transaction costs includes: (i) $64.9 million for the year ended December 31, 2024 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $8.8 million for the year ended December 31, 2024 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $4.6 million for the year ended December 31, 2024 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
We have reviewed your response to comment 2 and we believe that the non-GAAP adjustment for the purchase of royalty interest is inconsistent with Question 100.01 of the Compliance & Disclosure Interpretations on Non-GAAP Financial Measures.Rest of the question
Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.
No numbered answer found in the reply. Read the reply ↗
First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.
Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.
Adjusted EBITDA excludes from Net income (loss) the effect of Loss Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other (income) expense, net; non-operating (gain) loss on investments; debt extinguishment charges; Interest expense, net; Restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and goodwill impairment charges; and fair value charges on acquired inventory. charges. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted Adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.
Operating loss increased, income increased primarily due to the Goodwill impairment charge decrease in Purchase of $318.6 million, slightly offset by royalty interest and inventory fair value step-up amortization charges, the aforementioned gross profit increases and a $6.5 $2.6 million decrease in strategic transaction costs including the integration and transaction costs for the Lima Acquisition. Adjusted EBITDA increased primarily due to the aforementioned sales growth and gross profit increase. increase, driven by higher net sales and a decrease of $12.1 million in inventory fair value step-up amortization charges.
(7) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, the following non-GAAP measures for the three months ended April 4, 2025 as presented in our Form 10-Q for the period ended April 4, 2025 have been revised to reflect the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses: Adjusted EBITDA for our Recon segment has been revised from $68.3 million to $56.2 million, Total Adjusted EBITDA has been revised from $99.2 million to $87.1 million, Adjusted EBITDA margin for our Recon segment has been revised from 23.9% to 19.6%, and Total Adjusted EBITDA margin has been revised from 17.7% to 15.6%.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
We have reviewed your response to comment 3 and we believe that the non-GAAP adjustment for Inventory step-up in connection with acquired businesses is inconsistent with Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures.Rest of the question
Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.
We respectfully acknowledge the Staff’s comment and advise the Staff that the Company continues to believe that its non-GAAP adjustment for the purchase of royalty interest is appropriate for the reasons set forth below, as well as those set forth in our prior responses to the Staff.Read in the reply
April 8, 2026
The adjustment reflects the one-time, non-recurring, up-front expense recognized by the Company to acquire third-party royalty interests, which represents the purchase of a long-term economic right rather than a cost incurred in the ordinary course of producing or delivering the Company’s productsRest of the answer
or services. As described in the Company’s prior responses, the expense was incurred as part of a one-time, strategic decision to terminate existing product development agreements and acquire the associated royalty interests in connection with the transformation of the Company’s product development model and is fundamentally different from operating expenses incurred to run the Company’s business on a recurring basis. The Company does not anticipate entering into similar transactions on a recurring basis in connection with any future changes or additions to its core product development teams.
royalty buyouts were a foundational element of the Company’s transition to the new model, as they facilitated a shift in the way design surgeons are compensated for their development of the Company’s global product portfolio. The Company believes that this new model, which primarily aligns compensation with growth in the Company’s overall Reconstructive portfolio rather than individual products, will accelerate its pace of innovation by, among other things (i) incorporating new and diverse viewpoints to ensure that global and regional differences and preferences are considered in the product development process (which is of critical importance to the Company, given its expanded global reach following its acquisitions of Mathys and Lima), (ii) ensuring that the Company receives candid and unbiased guidance in integrating and rationalizing acquired product portfolios, (iii) placing additional emphasis on rapidly developing and expanding enabling technologies, and (iv) fostering an environment that encourages product development partners to provide strategic advice on research and development activities that cut across individual projects and product lines.
As noted above, a key benefit of the new model is the emphasis it places on candid and unbiased advice in the product development process. Under the Company’s legacy project-focused approach to innovation, product development partners were incentivized to devote their time and attention to projects to which they are assigned and to products for which they receive royalties. Consequently, these prominent partners with considerable clinical and design expertise may not be fully incentivized to provide broader ideas or innovative insights beyond the scope of their discrete engagements and may be less likely to provide high value innovative ideas to the Company in a project-focused setting because there are no incentives to do so.
Specifically, under the legacy model, if an idea for a next generation product could disrupt the existing portfolio or sunset certain products for which a product development partner currently receives royalties, they may be disincentivized from pursuing such an idea.
By terminating and buying out the royalty interests under the legacy agreements with its leading product development partners, the Company was able to significantly accelerate the shift to the new model by eliminating these disincentives, while also ensuring that it fulfilled its pre-existing contractual obligations under the legacy agreements through the negotiated settlements. The amounts to be paid each year under the buyout agreements are fixed and are not dependent on future operational factors. The buyout amounts were determined on an individual basis as a result of arm’s-length negotiations with the counterparties.
Additionally, the Company respectfully submits that the purchase of the royalty interest is not the type of “normal, recurring, cash operating expense” contemplated by Question
100.01 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures (each question thereof, a “C&DI”) because it is not a period operating cost incurred to generate current-period revenues, but rather a discrete transaction that restructures the economics of a pre-existing royalty arrangement by converting a contingent, sales-based obligation into a fixed purchase price. Stated differently, while ongoing royalties (if payable) may be recurring operating costs, the buyout of the royalty interest is a one-time strategic transaction to eliminate future contingent royalties and replace them with a single negotiated consideration amount and therefore is not indicative of the Company’s normal operating cost structure.
Further, to the extent the Staff’s “recurrence” concern is based on the fact that the acquired or underlying intellectual property may continue to be incorporated into the
Company’s products or that the purchase consideration may be settled over multiple periods, the Company respectfully submits that neither point changes the nature of the item being adjusted. The relevant question under Question 100.01 of the C&DI is whether the adjustment removes a normal, recurring operating expense, and the Staff has emphasized that the analysis turns on the nature and effect of the adjustment in the context of the business—not the timing of cash settlement. Here, the purchase reflects a discrete, negotiated restructuring of an economic right; once executed, the Company’s future recurring royalty expense under the terminated agreements is eliminated, rather than being
“normalized” out of operating results.
adjustment isolates a transaction that is fundamentally different from recurring operating costs incurred to operate the business. The Company respectfully submits that, under the
Staff’s own framework in Question 100.01 of the C&DI—which evaluates the nature, effect, and context of an adjustment—the exclusion of the purchase of royalty interest from Adjusted EBITDA and Adjusted Net Income does not obscure the Company’s operating performance and therefore does not render the measure misleading.
Moreover, the Company has clearly described the nature of the purchase of the royalty interest and the rationale for the adjustment, reconciled Adjusted EBITDA and Adjusted Net Income to the most directly comparable GAAP measures, and presented the GAAP measures with equal or greater prominence. The adjustment is applied consistently and is not selectively applied to exclude only unfavorable items.
stated in our Non-GAAP Measures disclosure in our periodic reports, Adjusted EBITDA is intended to facilitate period-over-period comparability by excluding items that “occur with inconsistent frequency,” “obscure underlying business trends,” or relate to “discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.” We believe the adjustment provides investors with a clear and meaningful view of our underlying business trends, aligns with how management evaluates the business and enhances comparability across periods.
For these reasons, as well as the reasons set forth in the Company’s prior responses to the Staff’s comments, the Company believes that excluding the purchase of the royalty interest from Adjusted EBITDA and Adjusted Net Income provides investors with a more meaningful depiction of the Company’s underlying operating performance and is consistent with
Regulation G and the guidance in Question 100.01 of the C&DI.
In future filings, the Company will supplement its disclosure regarding the adjustment to provide additional detail and context for why the Company believes such adjustment is useful to investors as follows:
“Purchase of royalty interest represents the one-time, up-front expense incurred by the Company to acquire the economic rights to future royalties under product development agreements in connection with the termination of such agreements as part of a strategic shift to a new product development model. The Company believes that excluding the impact of such expense enhances comparability between periods, provides investors with a clear and meaningful view of our underlying business trends and aligns with how management evaluates the ongoing business performance.”
2. We have reviewed your response to comment 3 and we believe that the non-GAAP adjustment for
Inventory step-up in connection with acquired businesses is inconsistent with Question 100.04 of the Compliance and Disclosure Interpretations on Non-GAAP Financial Measures. Please remove this non-GAAP adjustment from your presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in the press release on Form 8-K.
Response:
We respectfully acknowledge the Staff’s comment. The Company continues to believe that its non-GAAP adjustment for Inventory step-up in connection with acquired businesses
(i) is appropriate and consistent with Question 100.04 of the C&DI and the requirements of Rule 100(b) of Regulation G, (ii) enhances comparability between periods by removing the one-time, transaction-related Inventory step-up expense arising from the application of purchase accounting under GAAP that is not a reflection of our current or ongoing cost to manufacture product, and (iii) provides investors with a better understanding of the Company’s business performance and underlying gross margin trends. The adjustment is intended to eliminate the impact of a one-time, transaction-related step-up to reflect cost of goods sold as if such acquired inventory had been produced by the Company and sold in the ordinary course of business, absent which we believe the Company’s gross margins would have been viewed by investors as artificially low and distorted during the period when step-up charges were recognized in cost of goods sold. We believe that such an adjustment is particularly useful to investors in the context of a significant acquisition of a company that is engaged in the inventory and capital-intensive large joint implant business, such as Lima, which had approximately 16 months of inventory on hand as of the date of acquisition. We believe that this adjustment significantly enhanced comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance. This is further evidenced by the fact that following the completion of amortization of the Inventory step-up from its recently acquired businesses, the Company’s
GAAP gross margin remains on trend with our previously reported adjusted gross margins.
However, we understand and respect the Staff’s position and will remove this non-GAAP adjustment from our presentation of Adjusted EBITDA and Adjusted Net Income in future filings, including the presentation in press releases on Form 8-K.
First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.
Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.
(7) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, the following non-GAAP measures for the three months ended April 4, 2025 as presented in our Form 10-Q for the period ended April 4, 2025 have been revised to reflect the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses: Adjusted EBITDA for our Recon segment has been revised from $68.3 million to $56.2 million, Total Adjusted EBITDA has been revised from $99.2 million to $87.1 million, Adjusted EBITDA margin for our Recon segment has been revised from 23.9% to 19.6%, and Total Adjusted EBITDA margin has been revised from 17.7% to 15.6%.
(1) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for the three months ended April 4, 2025 has been revised from $99.2 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $87.1 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted EBITDA margin for the three months ended April 4, 2025 from 17.7%, as presented in our Form 10-Q for the period ended April 4, 2025, to 15.6%.
(1) For the three months ended April 3, 2026, we revised our definition of Adjusted EBITDA to no longer adjust for inventory step-up charges. Adjusted EBITDA in prior periods has been revised to reflect this change for consistency of presentation. Accordingly, Adjusted EBITDA for our Recon segment for the three months ended April 4, 2025 has been revised from $68.3 million, as presented in our Form 10-Q for the period ended April 4, 2025, to $56.2 million, reflecting the removal of a $12.1 million adjustment for inventory step-up in connection with acquired businesses, resulting in a corresponding reduction to Adjusted EBITDA margin for our Recon segment for the three months ended April 4, 2025 from 23.9%, as presented in our Form 10-Q for the period ended April 4, 2025, to 19.6%.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
We note your response to prior comment 4. To the extent that the non-GAAP adjustments for strategic transaction costs continue to be material to the non-GAAP measures, in future filings please include more detailed quantitative and qualitative information about the nature of the adjustments, similar to your response.
We respectfully acknowledge the Staff’s comment. We have included more detailed quantitative and qualitative information about the nature of such adjustments in our Form 10-K for the year ended December 31, 2025, and will continue to provide such information in future filings to the extent that non-GAAP adjustments for strategic transaction costs continue to be material to our non-GAAP measures.Read in the reply
10-K for the Fiscal Year Ended December 31, 2025
Consolidated
Financial Statements
Note
19. Segment Information, page 106
First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.
Non-GAAP Measures: 63 paragraphs changed; the 3 closest in words to the question are below.
Adjusted EBITDA excludes from Net income (loss) the effect of Loss Income (loss) from discontinued operations, net of taxes; Income tax expense (benefit); Other (income) expense, net; non-operating (gain) loss on investments; debt extinguishment charges; Interest expense, net; Restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; strategic purchase of economic interest on future royalty payments; and goodwill impairment charges; and fair value charges on acquired inventory. charges. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted Adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.
(5) Strategic transaction costs includes: (i) $9.2 $7.4 million for the three months ended October April 3, 2025 2026 and $17.5 $8.7 million for the three months ended September 27, 2024 April 4, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to be the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company (in each case, such costs relate solely to roles eliminated or that in connection with the integration of the Lima acquisition, and are dedicated to integration activities, non-recurring and not part of our normal business operations); (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling, labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $6.1 $3.4 million for the three months ended October April 3, 2025 2026 and $2.6 $2.9 million for the three months ended September 27, 2024 April 4, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $0.4 $0.2 million for the three months ended October April 3, 2025 2026 and $1.3 $0.5 million for the three months ended September 27, 2024, April 4, 2025, respectively, related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Condensed Consolidated Statements of Operations.
Selling, general and administrative expense increased $13.7 $13.8 million in the three months ended October April 3, 2025 2026 compared to the prior year period, primarily due to a $9.2 $4.6 million increase in commissions on increased sales and sales, increased investment in the business in selling, general and administrative costs of $10.3 $7.7 million, offset by and a $5.7 $1.1 million decrease increase in strategic transactions transaction costs driven by a reduction in acquisition integration costs.
Paragraphs where only numbers, dates or period words changed are not shown. Cut words struck through, new words highlighted.
We note your response to comment 1 and reissue in part. Please disclose how the CODM uses the reported measure of segment profit or loss in assessing segment performance and deciding how to allocate resources in future filings. Refer to ASC 280-10-50-29(f) and the example in ASC 280-10-55-47(bb).
We respectfully acknowledge the Staff’s comment. We have revised our disclosure in our Form 10-K for the year ended December 31, 2025 in response to the Staff’s comment, and will continue to provide such disclosure in future filings.Read in the reply
First report after the company's reply of Apr 8, 2026: 10-Q filed May 7, 2026 ↗, against the 10-Q filed Nov 6, 2025 ↗.
The part of the filing the question names could not be found in both reports. Read them on sec.gov.
Also in this review: closing letter, 2026-04-23